Primary Hyperoxaluria (PH) - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4564656
  • Drug Pipelines
  • 117 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Allena Pharmaceuticals
  • Alnylam Pharmaceuticals
  • OxThera
  • MORE
‘Primary Hyperoxaluria (PH) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Primary Hyperoxaluria (PH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Primary Hyperoxaluria (PH) - Disease Understanding and Treatment Algorithm

The Primary Hyperoxaluria (PH) market report gives the thorough understanding of the Primary Hyperoxaluria (PH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Primary Hyperoxaluria (PH) in the US, EU5, and Japan.

Primary Hyperoxaluria (PH) Epidemiology

The Primary Hyperoxaluria (PH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, Type specific diagnosed prevalent cases (PH Type 1, 2, 3 & unclassified) and Age-Specific diagnosed prevalent cases) scenario of Primary Hyperoxaluria (PH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, the total number of diagnosed prevalent population of Primary Hyperoxaluria (PH) was found to be 3,714, in the year 2016.

Primary Hyperoxaluria (PH) Drug Chapters

This segment of the Primary Hyperoxaluria (PH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, there is no FDA approved therapy for the treatment of Primary Hyperoxaluria in the United States and the current therapeutic market for Primary Hyperoxaluria is based on the therapies such as Enzyme reactivation therapy, Gene therapies and Substrate reduction therapy through RNA-interference. Treatment options for primary hyperoxaluria include alkaline citrate, orthophosphate, or magnesium. Upcoming therapies such as Oxabact (OxThera), ALLN-177 (Allena Pharmaceuticals) and Lumasiran (Alnylam Pharmaceuticals), have the potential to create a significant positive shift in the Primary Hyperoxaluria market size.

Primary Hyperoxaluria (PH) Market Outlook

The Primary Hyperoxaluria (PH) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Primary Hyperoxaluria (PH) in 7MM was found to be USD 330.58 million in 2016.

Primary Hyperoxaluria (PH) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Primary Hyperoxaluria (PH) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Primary Hyperoxaluria (PH) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Primary Hyperoxaluria (PH) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits:
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Primary Hyperoxaluria (PH) market
  • Organize sales and marketing efforts by identifying the best opportunities for Primary Hyperoxaluria (PH) market
  • To understand the future market competition in the Primary Hyperoxaluria (PH) market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allena Pharmaceuticals
  • Alnylam Pharmaceuticals
  • OxThera
  • MORE
1. Key Insights

2. Primary Hyperoxaluria Market Overview at a Glance
2.1. Market Share (%) Distribution of Primary Hyperoxaluria in 2017
2.2. Market Share (%) Distribution of Primary Hyperoxaluria in 2027

3. Disease Background and Overview: Primary Hyperoxaluria (PH)
3.1. Introduction
3.2. Symptoms
3.3. Genetic basis of Primary Hyperoxaluria
3.4. Classification
3.5. Etiology
3.6. Pathophysiology
3.7. Diagnosis
3.8. Management

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Forecast Methodology

5. 7MM Total Diagnosed Prevalent Patient Population of Primary Hyperoxaluria

6. Country Wise-Epidemiology of Primary Hyperoxaluria
6.1. United States
6.1.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the United States
6.1.2. Type Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in the United States
6.1.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in the United States
6.2. EU5 Countries
6.3. Germany
6.3.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany
6.3.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany
6.3.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany
6.4. France
6.4.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in France
6.4.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in France
6.4.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in France
6.5. Italy
6.5.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy
6.5.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy
6.5.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy
6.6. Spain
6.6.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain
6.6.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain
6.6.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain
6.7. United Kingdom
6.7.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the United Kingdom
6.7.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United Kingdom
6.7.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in United Kingdom
6.8. Japan
6.8.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan
6.8.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan
6.8.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan

7. Treatment Algorithm, Current Treatment, and Medical Practices

8. Unmet Needs

9. Emerging Drugs
9.1. Key Cross Competition
9.2. Oxabact: OxThera
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Advantages and Disadvantages
9.2.6. Product Profile
9.3. Lumasiran: Alnylam Pharmaceuticals
9.3.1. Product Description
9.3.2. Other Development Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Advantages and Disadvantages
9.3.6. Product Profile
9.4. ALLN-177: Allena Pharmaceuticals
9.4.1. Product Description
9.4.2. Regulatory Milestones
9.4.3. Clinical Development
9.4.4. Advantages and Disadvantages
9.4.5. Product Profile

10. Primary Hyperoxaluria: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of Primary Hyperoxaluria in 7MM

11. The United States Market Outlook
11.1. United States Market Size
11.2. Total Market size of Primary Hyperoxaluria
11.3. Market Size by Therapies

12. EU-5 Countries: Market Outlook
12.1. Germany
12.1.1. Total Market size of Primary Hyperoxaluria in Germany
12.1.2. Market Size by Emerging Therapies
12.2. France
12.2.1. Total Market size of Primary Hyperoxaluria
12.2.2. Market Size by Emerging Therapies
12.3. Italy
12.3.1. Total Market size of Primary Hyperoxaluria
12.3.2. Market Size by Emerging Therapies
12.4. Spain
12.4.1. Total Market size of Primary Hyperoxaluria
12.4.2. Market Size by Emerging Therapies
12.5. United Kingdom
12.5.1. Total Market size of Primary Hyperoxaluria
12.5.2. Market Size by Emerging Therapies
12.6. Japan: Market Outlook
12.6.1. Total Market size of Primary Hyperoxaluria
12.6.2. Market Size by Emerging Therapies

13. Market Drivers

14. Market Barriers

15. Appendix
15.1. Report Methodology

16. Capabilities

17. Disclaimer

18. About the Publisher

List of Tables
Table 1: Comparison between Primary and Secondary hyperoxaluria
Table 2: Patient characteristics at last study follow-up; patients diagnosed at paediatric age versus adult age in separate columns (PH Type 1)
Table 3: Characteristics of infantile cases of PH1 by genotype
Table 4: Percentage of the most common mutations identified from 222 alleles
Table 5: Comparing the different types of Primary Hyperoxaluria
Table 6: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the 7MM (2016-2027)
Table 7: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the United States (2016-2027)
Table 8: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Table 9: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Table 10: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany (2016-2027)
Table 11: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Table 12: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Table 13: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in France (2016-2027)
Table 14: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Table 15: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Table 16: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy (2016-2027)
Table 17: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Table 18: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Table 19: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain (2016-2027)
Table 20: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Table 21: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Table 22: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the UK (2016-2027)
Table 23: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the UK (2016-2027)
Table 24: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the UK (2016-2027)
Table 25: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan (2016-2027)
Table 26: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)
Table 27: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)
Table 28: Comparison of emerging drugs under development
Table 29: Oxabact, Clinical Trial Description, 2017
Table 30: Lumasiran, Clinical Trial Description, 2017
Table 31: ALLN-177, Clinical Trial Description, 2017
Table 32: 7 Major Market Size of Primary Hyperoxaluria in USD Million (2016-2027)
Table 33: United States Market Size of Primary Hyperoxaluria in USD Million (2016-2027)
Table 34: Market size of Primary Hyperoxaluria by therapies in the United States, in USD Million (2016-2027)
Table 35: Market Size of Primary Hyperoxaluria in Germany, in USD Million (2016-2027)
Table 36: Market Size of Primary Hyperoxaluria by therapies in Germany, in USD Million (2016-2027)
Table 37: Market Size of Primary Hyperoxaluria in France, in USD Million (2016-2027)
Table 38: Market Size of Primary Hyperoxaluria by therapies in France, in USD Million (2016-2027)
Table 39: Market Size of Primary Hyperoxaluria in Italy, in USD Million (2016-2027)
Table 40: Market Size of Primary Hyperoxaluria by therapies in Italy, in USD Million (2016-2027)
Table 41: Market Size of Primary Hyperoxaluria in Spain, in USD Million (2016-2027)
Table 42: Market Size of Primary Hyperoxaluria by therapies in Spain, in USD Million (2016-2027)
Table 43: Market Size of Primary Hyperoxaluria in the UK, in USD Million (2016-2027)
Table 44: Market Size of Primary Hyperoxaluria by therapies in the UK, in USD Million (2016-2027)
Table 45: Market Size of Primary Hyperoxaluria in Japan, in USD Million (2016-2027)
Table 46: Market Size of Primary Hyperoxaluria by therapies in Japan, in USD Million (2016-2027)

List of Figures
Figure 1: Calcium Oxalate deposits in the urinary space and in the renal tissue
Figure 2: Bone Oxalosis
Figure 3: Main routes of glyoxalate metabolism in a human hepatocyte
Figure 4: Metabolism of oxalate and renal outcome in patients with Primary Hyperoxaluria type 1
Figure 5: Total Diagnosed Prevalent Patient Population of Primary Hyperoxaluria in the 7MM (2016-2027)
Figure 6: Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Figure 7: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Figure 8: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Figure 9: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany (2016-2027)
Figure 10: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Figure 11: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Figure 12: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in France (2016-2027)
Figure 13: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Figure 14: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Figure 15: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy (2016-2027)
Figure 16: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Figure 17: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Figure 18: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain (2016-2027)
Figure 19: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Figure 20: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Figure 21: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the UK (2016-2027)
Figure 22: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the UK (2016-2027)
Figure 23: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the UK (2016-2027)
Figure 24: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan (2016-2027)
Figure 25: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)
Figure 26: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)
Figure 27: Unmet Needs of Primary Hyperoxaluria
Figure 28: 7 Major Market Size of Primary Hyperoxaluria in USD Million (2016-2027)
Figure 29: Market Size of Primary Hyperoxaluria in the US, USD Millions (2016-2027)
Figure 30: Market size of Primary Hyperoxaluria by therapies in the US, in USD Million (2016-2027)
Figure 31: Market Size of Primary Hyperoxaluria in Germany, USD Millions (2016-2027)
Figure 32: Market Size of Primary Hyperoxaluria by therapies, in Germany, in USD Million (2016-2027)
Figure 33: Market Size of Primary Hyperoxaluria in France, USD Millions (2016-2027)
Figure 34: Market Size of Primary Hyperoxaluria by therapies, in France, in USD Million (2016-2027)
Figure 35: Market Size of Primary Hyperoxaluria in Italy, USD Millions (2016-2027)
Figure 36: Market Size of Primary Hyperoxaluria by therapies in Italy, in USD Million (2016-2027)
Figure 37: Market Size of Primary Hyperoxaluria in Spain, USD Millions (2016-2027)
Figure 38: Market Size of Primary Hyperoxaluria by therapies in Spain, in USD Million (2016-2027)
Figure 39: Market Size of Primary Hyperoxaluria in the UK, USD Millions (2016-2027)
Figure 40: Market Size of Primary Hyperoxaluria by therapies in the UK, in USD Million (2016-2027)
Figure 41: Market Size of Primary Hyperoxaluria in Japan, USD Millions (2016-2027)
Figure 42: Market Size of Primary Hyperoxaluria by therapies in Japan, in USD Million (2016-2027)
Figure 43: Market Drivers
Figure 44:Market Barriers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • OxThera
  • Alnylam Pharmaceuticals
  • Allena Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll